Bone Health

Hematology

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Compendia

Respiratory

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

E-News

Print Subscription

BIOSIMILAR APPROVALS

Articles

Yukon, 1 of 3 Canadian territories, announced that it will implement a biosimilars switching policy, following Newfoundland and Labrador’s announcement to move forward with a similar policy earlier this week.

Yukon Becomes Tenth Canadian Jurisdiction to Add Biosimilars Switching Policy

The Increasing Access to Biosimilars Act of 2023 (HR 1352), a bill that would direct HHS to establish a demonstration project within Medicare that would establish a shared savings model for biosimilars, was introduced to the House of Representatives.

The Increasing Access to Biosimilars Act of 2023 Introduced to Congress

Newfoundland and Labrador is the latest Canadian province to implement a biosimilar switching policy, following in the footsteps of Ontario and 7 other jurisdictions.

Canadian Province Newfoundland and Labrador Adds Biosimilar Switching Policy

Posters presented by Alvotech at 2023 American Academy of Dermatology (AAD) annual meeting showcased proven bioequivalence and therapeutic equivalence candidate biosimilar AVT04 and reference ustekinumab (Stelara).

Favorable Equivalency Studies of Candidate Biosimilar AVT04 and Reference Ustekinumab

About

Contact

Advisory Board

Do Not Sell My Information

Terms & Conditions

Privacy Policy

Center for Biosimilars®

Facebook

Twitter

LinkedIn

Business Practice

Business

Development

Legal

Policy

Practice

Regulatory

1rem

Stakeholders Summit: Provider Education on Biosimilars

Videos

Pfizer's Citizen Petition on Biosimilar Communications

Combating Misinformation and Misconceptions About Biosimilars

Targeted Education for Biosimilar Stakeholders

US Versus EU Education on Biosimilars

The FDA's Approach to Biosimilar Education

Biosimilarity, Manufacturing Changes, and Comparability

Clinicians' Understanding of Manufacturing Changes

The Extrapolation of Indications

Selecting the Most Sensitive Population for Confirmatory Trials

Immunogenicity and Biosimilars

Misconceptions About Interchangeability

Clinical Studies for Biosimilars

The Future of US Biosimilars

The Role of Biosimilars in the US Healthcare System

Allowing the US Biosimilars Market to Flourish

Madelaine Feldman, MD: Prescribers' Understanding of Biosimilars

Molly Billstein Leber, PharmD, BCPS, FASHP: Dispelling Misconceptions About Biosimilar Approval and Use

Madelaine Feldman, MD: Physicians' Concerns Regarding Biosimilars

Molly Billstein Leber, PharmD, BCPS, FASHP: Pharmacists' Awareness of Biosimilars

Madelaine Feldman, MD: Practical Considerations for Biosimilars

Molly Billstein Leber, PharmD, BCPS, FASHP: Adoption of and Education on Biosimilars

Molly Billstein Leber, PharmD, BCPS, FASHP: Interchangeability Laws, Substitution, and the Future Role of Biosimilars